Sigma Labs Reports Second Quarter 2020 Financial Results

Companies Mentioned:

Primary Exchange: NASDAQ
Under the Symbol: SGLB

$2.76

($0.0750)

-2.6502


Sigma Labs Reports Second Quarter 2020 Financial Results

Thursday, July 23, 2020 4:01 PM

Selected by Global Manufacturer as its Preferred Monitoring Solution for 3D Metal Printers & Presented as PrintRite3D Ready

Management to Host Conference Call Today at 4:30 p.m. ET

SANTA FE, NM / ACCESSWIRE / July 23, 2020 / Sigma Labs, Inc. (NASDAQ:SGLB) ("Sigma Labs"), a leading developer of quality assurance software for the additive manufacturing industry, reported its financial and operational results for the second quarter ended June 30, 2020.

Key Second Quarter 2020 and Subsequent Operational Highlights

  • Selected by global manufacturer as its Preferred Monitoring Solution for 3D Metal Printers:
    • Partnership will provide major 3D printer manufacturer's global customer base with industry leading 3rd party IPQA® (In-process Quality Assurance) solution for its line of 3D printers. The manufacturer will present their printers as PrintRite3D® ready;
    • PrintRite3D will be actively promoted by a worldwide salesforce as their preferred monitoring solution; and
    • Initial purchase orders expected in the third quarter of 2020.
  • Launched @Sigma RTE program to provide potential end users and OEM's with a fast and inexpensive way to experience the benefits of Sigma's PrintRite3D IPQA® solution. Manufacturers worldwide will be able to experience using PrintRite3D® in real-time with their part design and chosen metal powder. Allows end users and global OEMs an opportunity to:
    • Experience in-process quality assurance and melt pool analytics in action;
    • Utilize Sigma's technology to improve build efficiency;
    • Learn how PrintRite3D can help ensure consistency and solve quality issue; and
    • Reduce product development time from initial design and simulation to production.
  • Secured Japanese Fortune Global 50 manufacturer as its first customer under the @Sigma RTE program with new purchase order for PrintRite3D.
  • Collaborated with NIST to outline how to calibrate PrintRite3D sensors to a traceable temperature standard.
    • Performed a first ever standards calibration with the renowned National Institute of Standards and Technology;
    • Opens the door for machine to machine calibration and enables machine matching for the Additive Manufacturing industry; and
    • Represents a major milestone to ensuring quality in production environments.
  • Appointed Mark K. Ruport as President and Chief Executive Officer, from his prior position as Executive Chairman, to further drive formation of strategic relationships, growth and sales strategies as the company commercializes its proprietary PrintRite3D technology. John Rice remains non-executive Chairman of the Board and has entered into a consulting contract with the company.
  • Fortified the balance sheet with $1.5 million in gross proceeds through an April 2020 offering of common stock and warrants, and $1.64 million in gross proceeds from the exercise of preferred warrants.

Management Commentary

"The second quarter of 2020 marks the continuation of the Company's strategic plan - Increasing sales of PrintRite3D, driven by multiple independent revenue streams with exciting progress being made on potential breakthrough contracts at the hardware OEM level," said Mark K. Ruport, President and Chief Executive Officer of Sigma Labs. "Thanks to our new @Sigma RTE program, we secured a Fortune Global 50 manufacturer at significantly lower cost of sales than previously possible. This new initiative shortens our sales cycle, is asset light and allows OEMs and end users to experience using our IPQA® system to improve build efficiency and ensure quality. Moreover, this initiative is an example of how Sigma adapted to the new COVID world and worked with our agent in Japan to bring a new customer to our testing lab without anyone leaving their respective office. We look forward to new announcements in the weeks to come on this front.

"Our customers are increasingly engaged with our sales staff, reaffirming what we always knew to be true - that the market momentum and increased demand for more agile manufacturing systems due to COVID has been an exciting tailwind for Sigma and our increasingly plug-and-play PrintRite3D product.

"On the financial front, our $1.5 million offering in April 2020 has served to fortify our balance sheet against market uncertainty resulting from the COVID-19 pandemic and subsequent macro-economic pressure. This, paired with a reduction in cash burn by over $100,000 per month, has better positioned us to weather any macro-economic storms that may arise over the coming months. Executive salary deferments and other cuts such as these stand as a testament to our team's belief in the long-term potential of our product and our commitment to create value for our shareholders.

"Over the coming months, I will continue to focus my efforts on four main areas: Increasing quarter-over quarter revenue driven by multiple independent revenue streams; driving multi-unit sales of PrintRite3D Production Series by end users that have validated our technology through the @Sigma RTE program; forming new strategic alliances and OEM contracts with both additive manufacturing hardware and software companies that provide sales leverage and market validation; and continued success with R&D organizations and Universities with advanced manufacturing programs, training tomorrow's manufacturing leaders on the value of a 3rd party, standards-based IPQA® solution for 3D printing.

"As evidenced by these new wins, the customer evolution has migrated from R&D to End Users to now OEMs. I believe that we are on the cusp of the industrialization of 3D metal printing and PrintRite3D is positioned as a critical component, or the missing link, in Additive Manufacturing's digital chain. Today, we have initiatives in India, Japan, throughout Europe and in countries like Turkey, all accelerating their adoption of AM to lessen their dependency on other countries and increasing their ability to be self-sufficient in times of crisis.

"The macro backdrop for additive manufacturing has never been stronger and Sigma is now uniquely positioned to set the standard for quality assurance for Additive Manufacturing. Despite the COVID crisis, we have strengthened our balance sheet, preserved our cash and added additional sales and marketing resources, positioning the company for strong growth as the economy improves. We look forward to sharing more on our developing story at upcoming virtual events in the third quarter," concluded Ruport.

Second Quarter 2020 Financial Results

Revenue for the second quarter of 2020 totaled $0.2 million. This compares to revenues of $34 thousand for the second quarter of 2019. The increase in revenue was due to a PrintRite3D® unit sale, as well as revenue recognized under the legacy Rapid Test and Evaluation ("RTE") program and an in-house RTE during the quarter.

Gross profit for the second quarter of 2020 was $0.1 million as compared to negative $27 thousand in the second quarter of 2019.

Total operating expenses for the second quarter of 2020 were $1.53 million as compared to total operating expenses of $1.57 million for the same period in 2019.

Cash used in operating activities for the six months ended June 30, 2020 totaled $2.4 million compared to $2.7 million in the first six months ended June 20, 2019. Approximately $400 thousand of this amount was due to trade accounts payables carried over from 2019 due to a delay in financing.

Net loss for the second quarter of 2020 was $1.6 million, or $(0.49) per share, as compared to a net loss of $1.6 million, or $(1.50) per share, in the second quarter of 2019.

Cash totaled $2.5 million at June 30, 2020, as compared to $0.6 million at March 31, 2020 and $0.6 million at June 30, 2019.

Second Quarter 2020 Results Conference Call

Sigma Labs President and CEO Mark Ruport and CFO Frank Orzechowski will host the conference call, followed by a question and answer period.

To access the call, please use the following information:

Date:

Thursday, July 23, 2020

Time:

4:30 p.m. Eastern time, 1:30 p.m. Pacific time

Toll-free dial-in number:

1-877-407-9039

International dial-in number:

1-201-689-8470

Conference ID:

13706559

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.

The conference call will be broadcast live and available for replay at http://public.viavid.com/index.php?id=140600 and via the investor relations section of the Company's website at www.sigmalabsinc.com.

A replay of the conference call will be available after 7:30 p.m. Eastern time through August 6, 2020.

Toll-free replay number:

1-844-512-2921

International replay number:

1-412-317-6671

Replay ID:

13706559

About Sigma Labs

Sigma Labs Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D® brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D® for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs' software product is a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.sigmalabsinc.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors, including, but not limited to, the uncertain effect of the COVID-19 pandemic on the Company's business, results of operations and financial condition, which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K (including but not limited to the discussion under "Risk Factors" therein) filed with the SEC on March 24, 2020 and which may be viewed at www.sec.gov.

Investor Contact:
Chris Tyson
Managing Director
MZ Group - MZ North America
949-491-8235
[email protected]
www.mzgroup.us

Company Contact:
Steven Gersten
Sigma Internal IR
[email protected]

Sigma Labs, Inc.
Condensed Balance Sheets
(Unaudited)

             
 
  June 30,
2020
    December 31,
2019
 
 
           
ASSETS
           
Current Assets:
           
Cash
  2,445,766     86,919  
Accounts Receivable, net
    286,405       55,540  
Inventory
    585,640       598,718  
Prepaid Assets
    118,031       199,727  
Total Current Assets
    3,435,842       940,904  
 
               
Other Assets:
               
Property and Equipment, net
    117,006       128,723  
Intangible Assets, net
    644,286       569,341  
Investment in Joint Venture
    -       500  
Long-Term Prepaid Asset
    52,000       52,000  
Total Other Assets
    813,292       750,564  
 
               
TOTAL ASSETS
  4,249,134     1,691,468  
 
               
LIABILITIES AND STOCKHOLDERS' EQUITY
               
 
               
Current Liabilities:
               
Accounts Payable
  295,220     727,114  
Notes Payable
    -       50,000  
Deferred Revenue
    99,588       139,447  
Accrued Expenses
    272,442       122,658  
Total Current Liabilities
    667,250       1,039,219  
 
               
Long-Term Liabilities:
               
CARES Act Deferred Payroll Tax Liability
    22,072       -  
Total Long-Term Liabilities
    22,072       -  
 
               
TOTAL LIABILITIES
    689,322       1,039,219  
 
               
Stockholders' Equity
               
Preferred Stock, $0.001 par; 10,000,000 shares authorized; 333 and 0 issued and outstanding, respectively
    1       -  
Common Stock, $0.001 par; 12,000,000 shares authorized; 3,926,362 and 1,403,759 issued and outstanding, respectively
    3,926       1,404  
Additional Paid-In Capital
    33,151,829       26,746,439  
Accumulated Deficit
    (29,595,944 )     (26,095,594 )
Total Stockholders' Equity
    3,559,812       652,249  
 
               
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
  4,249,134     1,691,468  
                 

Sigma Labs, Inc.
Condensed Statements of Operations
(Unaudited)

 
  Three Months Ended
June 30,
    Six Months Ended
June 30,
 
 
  2020     2019     2020     2019  
 
                       
REVENUES
  167,688     33,582     389,418     98,032  
 
                               
COST OF REVENUE
    57,684       60,625       302,387       157,180  
 
                               
GROSS PROFIT (LOSS)
    110,004       (27,043)       87,031       (59,148)  
 
                               
OPERATING EXPENSES:
                               
Salaries & Benefits
    605,295       581,356       1,257,492       1,093,916  
Stock-Based Compensation
    270,818       220,360       424,989       474,566  
Operating R&D Costs
    111,647       118,845       165,335       264,117  
Investor & Public Relations
    171,287       157,318       409,555       315,107  
Legal & Professional Service Fees
    219,007       218,919       430,515       403,489  
Office Expenses
    78,843       184,068       226,590       350,178  
Depreciation & Amortization
    17,970       49,203       35,983       97,586  
Other Operating Expenses
    51,687       38,994       135,736       77,203  
Total Operating Expenses
    1,526,554       1,569,064       3,086,195       3,076,162  
 
                               
LOSS FROM OPERATIONS
    (1,416,550 )     (1,596,107 )     (2,999,164 )     (3,135,310 )
 
                               
OTHER INCOME (EXPENSE)
                               
Interest Income
    31       7,016       882       12,798  
State Incentives
    151,657       -       151,657       51,877  
Exchange Rate Gain (Loss)
    (31 )     (2,264 )     (1,422 )     (2,710 )
Interest Expense
    (6,244 )     (2,136 )     (6,675 )     (4,258 )
Loss on Dissolution of Joint Venture
    (201 )     -       (201 )        
Other Income
    361,700       -       361,700       -  
Total Other Income (Expense)
    506,912       2,616       505,941       57,707  
 
                               
LOSS BEFORE PROVISION FOR INCOME TAXES
    (909,638)       (1,593,491)       (2,493,223)       (3,077,603)  
 
                               
Provision for income Taxes
    -       -       -       -  
 
                               
Net Loss
  (909,638)     (1,593,491)     (2,493,223)     (3,077,603)  
 
                               
Preferred Dividends
    (691,880 )     -       (1,007,127 )     -  
 
                               
Net Loss Applicable to Common Stockholders
  (1,601,518)     (1,593,491)     (3,500,350)     (3,077,603)  
 
                               
Net Loss per Common Share - Basic and Diluted
  (0.49)     (1.50)     (1.48)     (3.10)  
 
                               
Weighted Average Number of Shares Outstanding - Basic and Diluted
    3,256,098       1,077,759       2,359,862       1,006,381  
 
                               

Sigma Labs, Inc.
Condensed Statements of Cash Flows
(Unaudited)

       
 
  Six Months Ended  
 
  June 30,
2020
    June 30,
2019
 
OPERATING ACTIVITIES
           
Net Loss
  (2,493,223 )   (3,077,603 )
Adjustments to reconcile Net Loss to Net Cash used in operating activities:
               
Noncash Expenses:
               
Depreciation and Amortization
    35,983       97,586  
Stock Based Compensation
    424,989       474,150  
Securities Issued for Third Party Services
    54,924       -  
Change in assets and liabilities:
               
Accounts Receivable
    (230,865 )     818  
Interest Receivable
    -       27,038  
Inventory
    13,078       (330,340 )
Prepaid Assets
    81,695       (1,463 )
Accounts Payable
    (431,893 )     150,567  
Deferred Revenue
    (39,860 )     27,275  
Accrued Expenses
    149,785       (105,678 )
NET CASH USED IN OPERATING ACTIVITIES
    (2,435,387 )     (2,737,650)  
 
               
INVESTING ACTIVITIES
               
Purchase of Property and Equipment
    (11,474 )     (23,796 )
Purchase of Intangible Assets
    (87,736 )     (107,124 )
Payment Received from Notes Receivable
    -       15,000  
Dissolution of Joint Venture
    500       -  
NET CASH USED IN INVESTING ACTIVITIES
    (98,710 )     (115,920)  
 
               
FINANCING ACTIVITIES
               
 
               
Gross Proceeds from Public and Private Issuances of Securities
    3,600,000       2,521,220  
Less Offering Costs
    (820,228 )     (326,890 )
Payment of Note Payable
    (50,000 )     -  
Proceeds from Exercise of Warrants
    2,141,100       75,848  
Deferral of Payroll Taxes under the CARES Act
    22,072       -  
NET CASH PROVIDED BY FINANCING ACTIVITIES
    4,892,944       2,270,178  
 
               
NET CHANGE IN CASH FOR PERIOD
    2,358,847       (583,392)  
 
               
CASH AT BEGINNING OF PERIOD
    86,919       1,279,782  
 
               
CASH AT END OF PERIOD
  2,445,766     696,390  
 
               
Supplemental Disclosures:
               
Noncash investing and financing activities disclosure:
               
Issuance of Common Shares for Conversion of Preferred Shares and Preferred Dividends
  3,417,967     -  
Issuance of Securities for services
  62,794     153,000  
Disclosure of cash paid for:
               
Interest
  9,359     2,514  
Income Taxes
  -     -  
                 

SOURCE:  Sigma Labs, Inc.


Subscribe to alerts from Investor Network
SHARE ARTICLE